Popular Oral Drug for Diabetes May Hold ‘Intriguing’ Side Benefit

(MedPage Today) — Type 2 diabetes patients starting on SGLT2 inhibitors had a sightly lower risk of autoimmune rheumatic diseases compared with those initiating sulfonylureas, a large retrospective Korean study found.
Over a median follow-up…